Natural Compound Salvianolic Acid C Activates Kidney-Protective Mitophagy Pathway in Diabetes
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
Summary
Diabetic kidney disease (DKD) is a leading cause of kidney failure worldwide, partly driven by damaged mitochondria accumulating in kidney tubule cells. Researchers discovered that a nuclear receptor called ESRRA switches on a gene (ATG5) that triggers selective mitochondrial recycling (mitophagy). When ESRRA or ATG5 is lost, damaged mitochondria pile up, fibrosis worsens, and kidney function declines. The team then identified salvianolic acid C (SAC), a natural plant compound, as a potent ESRRA activator. In diabetic mouse models, SAC restored mitophagy, improved kidney filtration, reduced protein leakage, and shifted arginine metabolism toward nitric oxide production rather than urea—protecting blood vessels and tubules. This work points to SAC as a promising first-in-class therapeutic for DKD.
Detailed Summary
Diabetic kidney disease affects roughly 40% of people with diabetes and is the single largest driver of end-stage renal disease globally. Despite widespread use of glucose- and blood-pressure-lowering drugs, many patients still progress to dialysis, underscoring the need for therapies that address underlying cellular dysfunction rather than just metabolic parameters. This study, published in Autophagy, focuses on impaired mitochondrial quality control in renal tubular epithelial cells (TECs) as a root cause of DKD progression.
The researchers first established clinical relevance by analyzing human DKD kidney biopsies and publicly available transcriptomic datasets. Both ESRRA (estrogen related receptor alpha) and ATG5 (autophagy related 5) protein and mRNA levels were markedly reduced in DKD tissue compared to controls. Critically, their abundance correlated positively with estimated glomerular filtration rate (eGFR) and inversely with albuminuria, suggesting these molecules are not bystanders but active participants in disease severity.
To dissect the mechanism, the team used conditional tubule-specific Esrra knockout mice and CRISPR-Cas9 knockout in primary TECs. Loss of ESRRA suppressed PINK1-dependent mitophagy, caused mitochondrial fragmentation and respiratory dysfunction (measured by oxygen consumption rate), increased reactive oxygen species, and drove tubulointerstitial fibrosis as quantified by Masson's trichrome and ACTA2 staining. Conversely, AAV-mediated re-expression of Esrra in tubules—or overexpression of Atg5 alone—was sufficient to restore mitophagy flux (confirmed by LC3-II turnover with bafilomycin A1 treatment) and attenuate renal injury in streptozotocin-induced diabetic mice. ChIP-qPCR and luciferase reporter assays confirmed that ESRRA directly binds the ATG5 promoter and transactivates it.
Multi-omics screening (RNA-seq, metabolomics, and molecular docking) identified salvianolic acid C (SAC), a natural polyphenol from Salvia miltiorrhiza, as a high-affinity ESRRA agonist. Binding was validated by microscale thermophoresis (KD in the nanomolar range), surface plasmon resonance, and cellular thermal shift assay, with docking pinpointing three key residues: Asp326, Phe382, and Ala396. SAC stabilized ESRRA protein, upregulated ATG5, and restored mitophagy in high-glucose-treated TECs. In both db/db mice and high-fat diet/streptozotocin DKD models, SAC dose-dependently improved proteinuria, serum creatinine, BUN, mitochondrial respiration, and insulin sensitivity (HOMA-IR) without overt hepatic or systemic toxicity.
Metabolomic profiling revealed the downstream effector: ARG2 (arginase 2), a mitochondrial enzyme that normally converts L-arginine to urea, was selectively targeted for autophagy-lysosomal degradation by ESRRA-ATG5-driven mitophagy. With ARG2 degraded, L-arginine flux shifted away from urea production toward nitric oxide (NO) synthesis, supporting endothelial and tubular function. Exogenous L-arginine supplementation partially rescued renal injury in Esrra-deficient mice, confirming that arginine bioavailability is a key downstream mediator of the protective pathway. Together, these findings define an ESRRA→ATG5→mitophagy→ARG2 degradation→NO axis as a pivotal defense mechanism in DKD, and position SAC as a first-in-class, naturally derived therapeutic candidate warranting further clinical investigation.
Key Findings
- ESRRA and ATG5 protein levels were significantly reduced in human DKD biopsies and correlated positively with eGFR and inversely with albuminuria across patient cohorts.
- Tubule-specific Esrra knockout mice showed suppressed PINK1-dependent mitophagy, increased mitochondrial ROS, and exacerbated tubulointerstitial fibrosis compared to wild-type diabetic controls.
- AAV-mediated Esrra re-expression or Atg5 overexpression alone restored mitophagy flux and significantly attenuated renal fibrosis and tubular injury markers in diabetic mice.
- Salvianolic acid C (SAC) bound ESRRA at Asp326, Phe382, and Ala396 with nanomolar affinity (KD confirmed by MST and SPR), stabilized the receptor, and upregulated ATG5 expression.
- In db/db and HFD-STZ DKD mouse models, SAC dose-dependently improved proteinuria, serum creatinine, BUN, mitochondrial oxygen consumption rate, and HOMA-IR without overt toxicity.
- Metabolomic profiling showed ESRRA-ATG5-driven mitophagy selectively degraded ARG2 via the autophagy-lysosomal pathway, shifting L-arginine flux from urea toward nitric oxide synthesis.
- Exogenous L-arginine supplementation partially rescued renal injury in Esrra-deficient diabetic mice, confirming arginine bioavailability as a key mediator of the ESRRA protective axis.
Methodology
The study employed a multi-model approach including human DKD biopsy transcriptomics, tubule-specific conditional Esrra knockout mice, CRISPR-Cas9 knockout in primary mouse TECs, and AAV-mediated gene delivery in two independent DKD mouse models (db/db and HFD-STZ). Mechanistic binding studies used microscale thermophoresis, surface plasmon resonance, cellular thermal shift assay, and molecular docking. Transcriptional regulation was confirmed by ChIP-qPCR and luciferase reporter assays; downstream metabolomics profiled arginine pathway metabolites. Mitophagy flux was assessed by LC3-II turnover with bafilomycin A1, TEM ultrastructure, and mito-Keima reporter assays.
Study Limitations
The study is limited by the use of rodent DKD models, which may not fully recapitulate the heterogeneity of human diabetic nephropathy, and formal pharmacokinetic and phase I safety data for SAC in humans are not yet available. The mechanistic rescue experiments using exogenous L-arginine were partial, indicating additional downstream pathways remain uncharacterized. No conflicts of interest were declared by the authors, and the work was funded solely by the National Natural Science Foundation of China.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.